Valneva extends loans after chikungunya jab concerns
Vaccine specialist Valneva has refinanced its debt and cut its revenue forecast for this year after the US FDA suspended the licence for its chikungunya…
Valneva
Hot Topics
- March 9, 2026 | Real-time data on global dengue outbreaks
- November 5, 2025 | Davos brain health plan hopes to unlock Africa funds
- October 31, 2025 | GSK’s Q3 results buoyed by long-acting HIV jab
- October 27, 2025 | South Africa to make Gilead’s lenacapavir a ‘public good’
- October 24, 2025 | Sanofi Global Health Unit says 1 mln reached since 2021